# Dose Ranging Study of Glycopyrronium Bromide in Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease

> **NCT01703624** · PHASE2 · COMPLETED · sponsor: **Prosonix Limited** · enrollment: 37 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** glycopyrronium bromide

## Key facts

- **NCT ID:** NCT01703624
- **Lead sponsor:** Prosonix Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-08
- **Final completion:** 2013-09
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2016-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01703624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01703624, "Dose Ranging Study of Glycopyrronium Bromide in Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01703624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*